Telix Pharmaceuticals: Scope Of Company Beyond Radio Antibody-Drug Conjugate TLX591-Tx
2026-03-01 22:00:48 ET
The last time I spoke about Telix Pharmaceuticals ( TLX ) it was with respect to a Seeking Alpha article entitled " Telix Pharma Stock: Prostate Cancer Treatments Could Lead To Increased Value ." With respect to this article, I noted that the company was in the process of developing its PSMA-targeted radio antibody-drug conjugate [rADC] TLX591-Tx [lutetium 177Lu rosopatamab tetraxetan] for the treatment of patients with metastatic castration-resistant prostate cancer [mCRPC]. As an update, the company completed a total enrollment of 30 patients for Part 1 of the ProstACT Global phase 3 study targeting this group of cancer patients and has pressed on to Part 2, which is the randomized expansion portion of it....
Read the full article on Seeking Alpha
For further details see:
Telix Pharmaceuticals: Scope Of Company Beyond Radio Antibody-Drug Conjugate TLX591-Tx
NASDAQ: TLX
TLX Trading
-2.26% G/L:
$7.35 Last:
59,746 Volume:
$7.31 Open:
